Main pharmaceutical firms have disclosed their tentative third-quarter outcomes this 12 months, revealing starkly contrasting fortunes in key indicators of gross sales and working revenue. Whereas GC Biopharma recorded quarterly gross sales within the 600 billion gained vary for the primary time, its working revenue declined considerably, alongside Yuhan Corp. and Chong Kun Dang, which additionally confirmed reducing working income. In distinction, Daewoong Pharmaceutical achieved an working revenue progress charge within the 50% vary amid sturdy gross sales of flagship merchandise equivalent to Nabota and expertise switch revenues from subsidiaries, whereas Boryung and HK inno.N additionally continued their upward trajectory in working revenue.
Based on digital disclosures from the Monetary Supervisory Service on Nov. 10, GC Biopharma recorded the very best gross sales amongst pharmaceutical firms within the third quarter with 609.5 billion gained, a 31% improve in comparison with the identical interval final 12 months. Gross sales of pharmaceuticals together with COVID-19 therapy Paxlovid elevated, and steady progress in gross sales of blood product Alyglo from U.S. subsidiary ABO Holdings led to the primary quarterly gross sales within the 600 billion gained vary. Nonetheless, working revenue was calculated at 29.2 billion gained, a 26% lower, as a result of affect of large-scale investments by ABO Holdings and deteriorating profitability from declining vaccine gross sales. Kwon Hae-soon, a researcher at Eugene Funding & Securities, stated, “On condition that ABO Holdings is in its preliminary institution section, the sluggish restoration development of subsidiaries, and the necessity for continued analysis and improvement (R&D) and facility investments, efficiency ought to be seen from a mid-to-long-term perspective.”
Yuhan Corp. confirmed gross sales of 570 billion gained, down 4.8%, and working revenue of twenty-two billion gained, down 55%, as a result of reverse base impact of milestone revenues from non-small cell lung most cancers therapy Lazertinib acquired final 12 months. Elevated R&D prices from subsidiary Immunoncia additionally had an affect. Nonetheless, Search engine optimization Geun-hee, a researcher at Samsung Securities, anticipated future efficiency momentum, saying, “Milestone revenues from Lazertinib’s European and Chinese language launches are anticipated to be mirrored in fourth-quarter outcomes.”
Chong Kun Dang noticed gross sales improve 4.6% to 427.4 billion gained amid continued progress of flagship merchandise together with Godex, Fexclue, and Prolia, however working revenue decreased 18.7% to twenty.5 billion gained amid will increase in promoting, normal and administrative bills and R&D prices. Kim Hye-min, a researcher at KB Securities, gave a constructive analysis of Chong Kun Dang, saying, “Efficiency is steadily bettering, and R&D for brand new drug candidates equivalent to SkyReach biosimilar CKD-704 is steadily progressing.”
Conversely, Daewoong Pharmaceutical recorded working revenue of 56.9 billion gained, a 53% improve, as a result of progress in digital healthcare together with good mattress monitoring resolution Sync and powerful exports of botulinum toxin preparation Nabota. Nabota exports elevated 16% as gross sales via companions in the USA and Europe confirmed sturdy efficiency, dispelling considerations about demand slowdown. The digital healthcare division additionally continued its progress trajectory, recording gross sales of 12.8 billion gained. Park Jong-hyun, a researcher at Daol Funding & Securities, acknowledged, “Even in Europe, a comparatively weak area, Nabota was launched in France in July and fillers are scheduled to be launched subsequent 12 months, so gross sales progress is anticipated.”
Hanmi Pharmaceutical additionally noticed upward efficiency with working revenue of 55.1 billion gained (+8.1%) and gross sales of 362.3 billion gained (+0.1%). Specifically, gross sales of dyslipidemia therapy Rosuzet elevated 10%, sustaining progress regardless of the affect of drug value discount programs. Subsidiary Beijing Hanmi additionally recorded an working revenue margin of 25%, with operations normalizing. Kim Solar-ah, a researcher at Hana Securities, predicted, “By securing a full worth chain, value flexibility and provide stability may be leveraged as strengths to realize goal gross sales.”
In the meantime, Boryung achieved file highs with working revenue rising 51.3% to 29.4 billion gained and gross sales rising 3.3% to 280 billion gained. Robust efficiency of flagship merchandise together with hypertension new drug Canav household and gastric drugs GelfoS performed a big position.
HK inno.N confirmed gross sales of 260.8 billion gained, up 13.7%, and working revenue of 25.9 billion gained, up 16.4%, falling wanting market expectations because the H&B division together with Situation considerably underperformed as a result of recall impacts, regardless of sturdy efficiency within the prescription drug enterprise division with gastroesophageal reflux illness therapy Okay-CAP gross sales rising 30%. Jung Yu-kyung, a researcher at Shinhan Securities, identified, “Since continued gross sales progress of Okay-CAP, fluid preparations, and anticancer medication is anticipated, sturdy efficiency is anticipated for the prescription drug division,” including “Restoration in H&B division gross sales is the important thing to efficiency.”
